Open Access<p>Efficacy and Safety of Androgen-Deprivation Therapy Combined with Docetaxel Plus Prednisone in High-Burden Metastatic Hormone-Sensitive Prostate Cancer</p>
Author(s) -
Linjun Hu,
Qinxin Zhao,
Huaiyong Bai,
Chengming Xie,
Xingli Shan,
Dehu Lu,
Yonghai Chen,
Dongdong Han,
Zejun Xiao,
Jun Tian,
Dong Wang,
Xingang Bi,
Nianzeng Xing
Publication year - 2020
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s243843
Subject(s) - medicine , docetaxel , prednisone , androgen deprivation therapy , prostate cancer , urology , oncology , clinical endpoint , incidence (geometry) , regimen , prostate specific antigen , chemotherapy , gastroenterology , cancer , randomized controlled trial , physics , optics
The aim of this study was to evaluate the efficacy and safety of hormonal and synchronous docetaxel plus prednisone (DocP) in metastatic hormone-sensitive prostate cancer (mHSPC).